Emcure Pharma IPO subscription on July 3: Check details about company’s promoters before bidding

Emcure Pharmaceuticals IPO will open for subscription on July 3. The public issue consists of a fresh issue of 79 lakh shares aimed at raising ₹800 crore and an offer-for-sale (OFS) of 1.14 crore shares worth ₹1,152.03 crore. The company's promoters will participate in the OFS and offload some of their stakes.

Emcure Pharma IPO offer size, price band and lot size

Emcure Pharma’s public issue is a book-built issue valued at ₹1,952.03 crore. Emcure Pharma IPO price band is set at ₹960 to ₹1008 per share, with lot size of 14 shares.

The pharma company’s public issue combines a fresh issue of 79 lakh shares aimed at raising ₹800 crore with an offer for sale of 1.14 crore shares amounting to ₹1,152.03 crore. Retail investors, interested in applying for the Emcure Pharma IPO, can bid for a minimum of 1 lot comprising 14 shares, which aggregates to an investment of ₹14,112.

To know more and pre-apply for Emcure Pharma IPO, CLICK HERE

Promoters of the company

The promoters of the company include Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar and Samit Satish Mehta. The promoters jointly hold 54.42% stake, or 98,591,192 shares, in the company before the launch of the public issue. Members of the Promoter Group include Everest Trust, Unity Trust, Bhavana Satish Mehta and Pushpa Rajnikant Mehta among others.

The members of the promoter group hold 52,139,276 shares, or 28.79% stake, in the company jointly.

Satish Ramanlal Mehta, the Managing director of Emcure Pharmaceuticals, holds the maximum stake in the company among all the promoters. He holds 75,816,748 shares, or 41.85% stake, in the company pre-issue. He will sell up to 4.2 lakh equity shares of face value of ₹10 each via OFS. Satish Ramanlal Mehta started Emcure Pharma in 1981. He has also worked with various ministries of the government of India such as the Ministry of Human Resource Development and the NITI Aayog. He is an alumnus of Indian Institute of Management, Ahmedabad (IIM-A).

Read More: Who is Namita Thapar and how is she related to IPO-bound Emcure Pharma?

Samit Satish Mehta is the second biggest shareholder in the company and owns 7.48% stake in Emcure ahead of the issue. He will sell as much as 10,000 equity shares of face value of ₹10 each in the OFS, according to the RHP. Samit Satish Mehta also serves as the Executive Director, Operations, at Emcure. He is the Chief Operating Officer and Director of Gennova Biopharmaceuticals Ltd. Samit has significantly contributed in developing Emcure’s business in the United States, European Union and Canada. He is an alumnus of the Wharton School, University of Pennsylvania.

Namita Vikas Thapar holds the third largest stake in the company. She holds a 3.5% stake in Emcure Pharma. The Shark Tank India fame top executive joined the company as Chief Financial Officer in 1999. Namita Thapar will offload up to 12,68,600 shares of face value of ₹10 each in the IPO. She currently serves as the company’s Executive Director. She has invested in many companies as an angel investor. Namita holds a management degree from the Fuqua School of Business, Durham, and she is also a Chartered Accountant.

Sunil Rajanikant Mehta holds a 1.59% stake in the company and is the Whole-time Director of Emcure. He will offload as much as 40,000 shares of face value of ₹10 each via OFS. Mehta joined the company in 1983 and became a Board member in 2013. He has played an important role in the setting up of the company’s manufacturing facilities. Sunil Rajanikant Mehta is an alumnus of the Institute of Management Development and Research, Pune.

Emcure Pharma Financials

Emcure’s revenue from operations for the financial year ended March 31, 2024, increased over 11% to ₹6,658 crore from ₹5,985 crore in the preceding fiscal (FY23). The pharmaceutical company’s profit after tax (PAT) dropped over 6% to ₹527.58 crore in FY24 against ₹561.85 crore in FY23. The pharma company’s net worth surged 18% to ₹2,952.28 crore in FY24 against ₹2,501.13 crore in the preceding financial year.

About Emcure Pharma

Emcure Pharmaceuticals Limited is engaged in developing, manufactures, and marketing pharmaceutical products. The company has a presence in 70 countries and has 13 manufacturing facilities in India. The company manufactures pharmaceutical and biopharmaceutical products such as pills, liquids, injectables, complex ingredients such as chiral molecules, iron molecules and cytotoxic substances. Emcure emerged as the leading pharma company in gynaecology and HIV antiviral therapeutic areas for the 12-month period ending September 2023.

To know more about IPOs listing, schedule and upcoming IPOs, click here